Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $866.2 million.

  • Ptc Therapeutics' Total Current Liabilities rose 4184.18% to $866.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $866.2 million, marking a year-over-year increase of 4184.18%. This contributed to the annual value of $581.0 million for FY2024, which is 366.76% down from last year.
  • Per Ptc Therapeutics' latest filing, its Total Current Liabilities stood at $866.2 million for Q3 2025, which was up 4184.18% from $627.8 million recorded in Q2 2025.
  • Ptc Therapeutics' Total Current Liabilities' 5-year high stood at $866.2 million during Q3 2025, with a 5-year trough of $250.9 million in Q1 2021.
  • Over the past 5 years, Ptc Therapeutics' median Total Current Liabilities value was $509.3 million (recorded in 2021), while the average stood at $519.2 million.
  • Within the past 5 years, the most significant YoY rise in Ptc Therapeutics' Total Current Liabilities was 9499.83% (2022), while the steepest drop was 2024.39% (2022).
  • Quarter analysis of 5 years shows Ptc Therapeutics' Total Current Liabilities stood at $509.3 million in 2021, then decreased by 20.24% to $406.2 million in 2022, then surged by 48.46% to $603.1 million in 2023, then fell by 3.67% to $581.0 million in 2024, then soared by 49.1% to $866.2 million in 2025.
  • Its Total Current Liabilities stands at $866.2 million for Q3 2025, versus $627.8 million for Q2 2025 and $595.4 million for Q1 2025.